💊 Sosei continues Big Pharma alliances; WTO continues deferring decisions; China continues Covid transition
#240 | Whales make everything better
Hello, and welcome back for a brand new season of end-of-the-year Kables.
Eli Lilly is partnering with Sosei Heptares to develop GPCR modulators for diabetes and metabolic diseases with a $37 million upfront payment. This is Lilly's second major announcement of December, after its tie-up with Egypt's EVA Pharma for cheaper insulin in LMICs. Sosei, meanw…
Keep reading with a 7-day free trial
Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.
 |
|